Pulse Biosciences reported that 86% of 43 patients had at least 50% nodule shrinkage after 6 months, with no serious adverse events reported. These interim results favor the treatment’s prospects, though the group was small.
These results suggest the treatment may shrink nodules and ease symptoms without serious safety problems in the patients studied. The report covers only 43 people, so results from more patients are still needed.
Follow Pulse Biosciences, Inc. (PLSE) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for PLSE